Related Experiment Video
Updated: Aug 30, 2026
Heterotopic Auxiliary Whole Liver Rat Transplant Model Utilizing a Hepaticoureterostomy for Allograft Rejection Studies
Published on: March 8, 2024
Treatment of hepatitis C virus infection in the allograft
1Liver Unit, Queen Elizabeth Hospital, Birmingham, England. James.Neuberger@uhb.nhs.uk
Insights
Hepatitis C virus (HCV) recurrence post-transplant impacts graft survival. Strategies to reduce pretransplant HCV load and optimize immunosuppression may mitigate recurrence, though optimal treatments are still under investigation.
Area of Science:
- Hepatology
- Transplantation Immunology
- Virology
Background:
- Hepatitis C virus (HCV) recurrence post-liver transplant significantly diminishes graft survival and patient quality of life.
- Factors influencing HCV recurrence severity include pretransplant viral load, donor age, and ischemic time, with the impact of split livers remaining unclear.
Purpose of the Study:
- To review current strategies for mitigating HCV recurrence after liver transplantation.
- To evaluate the efficacy and limitations of existing and emerging treatments for HCV recurrence.
Main Methods:
- Literature review of studies on pretransplantation risk factors for HCV recurrence.
- Analysis of immunosuppression regimens and their association with viral replication and graft damage.
- Evaluation of interferon-based therapies and newer treatment modalities for HCV recurrence.
Main Results:
- Reducing pretransplant HCV viral load, avoiding older donor organs, and minimizing ischemic times may decrease recurrence severity.
- Aggressive immunosuppression and acute rejection treatment correlate with increased viral replication and graft injury.
- Pegylated interferon and ribavirin represent the current standard of care, despite frequent side effects and the need for optimized dosing and duration.
Conclusions:
- While pretransplantation interventions can influence HCV recurrence, optimal immunosuppression strategies require further definition.
- Current evidence does not support preemptive HCV treatment. Pegylated interferon and ribavirin, though imperfect, are cost-effective. The role of novel therapies is yet to be determined.
Abstract:
1. Recurrence of hepatitis C virus (HCV) in the graft is associated with a reduced quality of life and worse graft survival. 2. Pretransplantation, the severity of HCV recurrence may be reduced by reducing the pretransplantation load, by avoiding the use of organs from older donors, and by reducing the ischemic times. The effect of split livers on recurrence rates is uncertain. 3. The optimal immunosuppression regime has not been established but a heavy induction regime and treatment for acute rejection are associated with more viral replication and more graft damage. 4. Presently, there is no convincing evidence for preemptive treatment of HCV. 5. There are many studies on the effect of interferon with and without ribavirin for the treatment of HCV hepatitis. However, few are prospective, randomized, and controlled. 6. The current best treatment is with pegylated interferon and ribavirin; the dose and duration of treatment need to be established. Side-effects of treatment are common and reduction/withdrawal is frequent, but the regime is cost-effective. 7. The role of newer treatments remains to be established.
